EyePoint Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30233G2093
USD
13.73
0.15 (1.1%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Arbutus Biopharma Corp.
Arcutis Biotherapeutics, Inc.
Coherus BioSciences, Inc.
MacroGenics, Inc.
Nurix Therapeutics, Inc.
EyePoint Pharmaceuticals, Inc.
Erasca, Inc.
KalVista Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc.
Cullinan Therapeutics, Inc.
Icosavax, Inc.

Why is EyePoint Pharmaceuticals, Inc. ?

1
The company has declared negative results for the last 8 consecutive quarters
  • NET SALES(HY) At USD 1.32 MM has Grown at -96.35%
  • OPERATING CASH FLOW(Y) Lowest at USD -267.54 MM
  • ROCE(HY) Lowest at -102.71%
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 52.24%, its profits have fallen by -77.2%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is EyePoint Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
EyePoint Pharmaceuticals, Inc.
63.06%
0.72
68.72%
S&P 500
25.22%
1.92
13.25%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-1.85%
EBIT Growth (5y)
-235.26%
EBIT to Interest (avg)
-58.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.06
Sales to Capital Employed (avg)
0.23
Tax Ratio
0.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.41
EV to EBIT
-3.04
EV to EBITDA
-3.06
EV to Capital Employed
360.58
EV to Sales
23.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-11880.62%
ROE (Latest)
-75.78%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -152.44 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.96 times

-36What is not working for the Company
NET SALES(HY)

At USD 1.32 MM has Grown at -96.35%

OPERATING CASH FLOW(Y)

Lowest at USD -267.54 MM

ROCE(HY)

Lowest at -102.71%

DEBT-EQUITY RATIO (HY)

Highest at -86.88 %

PRE-TAX PROFIT(Q)

Lowest at USD -84.88 MM

NET PROFIT(Q)

Lowest at USD -84.83 MM

RAW MATERIAL COST(Y)

Grown by 171.3% (YoY

OPERATING PROFIT(Q)

Lowest at USD -86.59 MM

EPS(Q)

Lowest at USD -0.99

Here's what is working for EyePoint Pharmaceuticals, Inc.

Inventory Turnover Ratio
Highest at 1.96 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for EyePoint Pharmaceuticals, Inc.

Net Sales
At USD 1.32 MM has Grown at -96.35%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -84.88 MM has Fallen at -46.55%
over average net sales of the previous four periods of USD -57.92 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -84.83 MM has Fallen at -46.29%
over average net sales of the previous four periods of USD -57.99 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD -267.54 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit
Lowest at USD -84.88 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -84.83 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio
Highest at -86.88 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Profit
Lowest at USD -86.59 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (USD MM)

EPS
Lowest at USD -0.99
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Raw Material Cost
Grown by 171.3% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales